Best Astrocytoma doctors in Israel: TOP 7 doctors

Dr. Yuri Goldes is a general surgeon with more than 20 years of clinical experience. He specializes in upper gastrointestinal and oncologic surgery. He is Deputy Director of the Department of General Surgery and Transplantation at Sheba Medical Center in Tel Aviv. He also leads the Upper GI Surgery Unit. He was named to Forbes Israel’s Best Doctors in 2025. He is ranked among Israel’s Best Gastrointestinal Surgeons by Forbes. In 2019, he received the Israeli Ministry of Health “Best Doctor of the Year” award.

He is an expert in advanced minimally invasive and robotic surgery. He treats diaphragmatic hernia, achalasia, GERD, and gallbladder disease. He also performs oncologic surgery for pancreatic, gastric, and esophageal cancers. He uses laparoscopic and robotic techniques.

He pioneered some of Israel’s first robotic oncologic resections of the stomach and pancreas. He is among a small group worldwide who perform minimally invasive Whipple procedures (pancreaticoduodenectomy) using advanced laparoscopy. He applies methods that improve outcomes and speed recovery. He provides personalized care.

900+ procedures performed – Dr. Blumental is a highly experienced neuro-oncologist and director of the Neuro-oncology Service at Sourasky Medical Center.

• 30 years of experience of experience in oncology
• Director of Neuro-oncology Service at Huntsman Cancer Institute
• Trained at Memorial Sloan-Kettering Cancer Center
• Specializes in high success rate oncology treatments

Dr. Felix Bokstein leads the Neurooncology Clinic at Ichilov – one of Israel's largest and most advanced hospitals, focusing specifically on brain tumors.

• His primary focus is on treating complex brain and spinal cord tumors.
• As Head of Clinic, he oversees a dedicated neuro-oncology unit.
• Experience includes managing gliomas, astrocytomas, and other CNS malignancies.
• Integrates chemotherapy, targeted therapies, and clinical trial options into treatment plans.

Professor Zvi Ram heads the European Association of Neurosurgical Societies (EANS) – a top-level role that highlights his leadership in the field.

• He specializes in minimally invasive surgery and brain mapping techniques
• Expert in neurosurgical operations, including deep brain stimulation (DBS)
• Performs image-guided neurosurgery for brain tumors, trained in Greece and Switzerland
• Leads research into gene-based therapies for brain cancer
• Honored with the Borenstein Award from the Brain & Behavior Research Foundation

Prof. Zvi Cohen is Director of the Neurosurgery Department and the Neuro-Oncology Unit at Sheba Medical Center. He is a neurosurgeon and neuro-oncology expert. He was included in Forbes Israel’s Best Doctors 2025. He leads clinical research on drug therapies for malignant brain tumors. He also founded Sheba’s brain tumor tissue bank.

He is board-certified in neurosurgery. He trained at Tel Aviv University. He completed fellowships in neuroradiology at Beth Israel and in neurosurgical oncology at MD Anderson. His practice covers complex brain, pituitary, spine, and spinal cord tumors. He has expertise in stereotactic biopsies, image-guided resections, intraoperative MRI, navigation systems, and radiosurgery. He is a member of the Society for Neuro-Oncology and the Israeli Association of Neurological Surgeons.

Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.

He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.